Congratulations to IMPACT THERAP-B (Stock Code: 7630.hk) on the Successful IPO on the Main Board of the HKEX!

Congratulations to IMPACT THERAP-B (Stock Code: 7630.hk) on the Successful IPO on the Main Board of the HKEX!

Congratulatory

2026/05/13

Congratulations to

IMPACT THERAP-B (Stock Code: 7630.hk)

on the Successful IPO on the Main Board of the HKEX!

COMPANY PROFILE

Founded in 2009, Impact Therapeutics (IMPACT THERAP-B) is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

(Source：https://www.impacttherapeutics.com/）

CR SWCS Team is honoured to serve as

IMPACT THERAP-B's Joint Company Secretary,

committed to ensuring governance,

compliance, and sustained growth.

Other News

Decoding ESG Disclosure in Hong Kong IPOs at Shanghai Seminar

Congratulations to IMPACT THERAP-B (Stock Code: 7630.hk) on the Successful IPO on the Main Board of the HKEX!

CR SWCS 2025 Year-in-Review: Professional Services Empower Development, Outstanding Achievements Deliver Impressive Results (Content available in Chinese Only)

【ESG Outlook】Under the 15th Five-Year Plan, How Can Companies Seize ESG Strategic Opportunities? (Content available in Chinese Only)

Thought Leadership